A Study to Investigate the Effect of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of AZD2389

Trial Identifier: D7930C00004
Sponsor: AstraZeneca
Start Date: February 2025
Primary Completion Date: December 2025
Study Completion Date: December 2025
Condition: Liver, Pancreas & Gallbladder - Other

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
US, CA Rialto, CA, US, 92377
US, FL Miami Lakes, FL, US, 33014
US, FL Orlando, FL, US, 32809
US, TX San Antonio, TX, US, 78215